KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 80 filers reported holding KEROS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $53,447,522 | -20.7% | 1,676,522 | 0.0% | 0.10% | -18.6% |
Q2 2023 | $67,362,653 | -6.0% | 1,676,522 | -0.1% | 0.12% | -25.3% |
Q1 2023 | $71,651,368 | +7.2% | 1,678,018 | +20.5% | 0.16% | -38.8% |
Q4 2022 | $66,863,144 | +47.0% | 1,392,402 | +15.2% | 0.26% | +75.5% |
Q3 2022 | $45,475,000 | +39.9% | 1,208,822 | +2.8% | 0.15% | +69.0% |
Q2 2022 | $32,505,000 | -34.1% | 1,176,433 | +29.8% | 0.09% | -12.1% |
Q1 2022 | $49,291,000 | -9.1% | 906,433 | -2.2% | 0.10% | -1.0% |
Q4 2021 | $54,205,000 | +95.3% | 926,433 | +32.1% | 0.10% | +112.8% |
Q3 2021 | $27,748,000 | -7.1% | 701,433 | -0.3% | 0.05% | +6.8% |
Q2 2021 | $29,875,000 | -7.3% | 703,439 | +34.4% | 0.04% | -8.3% |
Q1 2021 | $32,218,000 | -12.5% | 523,439 | +0.3% | 0.05% | -20.0% |
Q4 2020 | $36,830,000 | +3083.2% | 522,121 | +1640.4% | 0.06% | +2900.0% |
Q3 2020 | $1,157,000 | +2.8% | 30,000 | 0.0% | 0.00% | -33.3% |
Q2 2020 | $1,125,000 | – | 30,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |